September 2017

Five years ago, Capital BlueCross asked community oncology practices in its network what kind of reimbursement model they would like to try as they worked to stay financially viable and independent.

Chimeric antigen receptor T-cell therapy may soon hit the market, and numerous cancer care centers are poised to offer this for what may be the first FDA-approved indication: relapsed/refractory B-cell acute lymphoblastic leukemia.

Outpatient branded drug sales in the 340B Drug Pricing Program now amount to almost 8% of the total market, well up from 5.4% in 2012.

It is not far-fetched to believe that, one day soon, automated systems will be able to obtain payer approval for therapies without any human involvement.

Despite all the excitement and anticipation, there is a growing anxiety among payers and providers regarding the cost of CAR T cells.

The Association of Community Cancer Centers has long recognized the principle of mass-producing success based on an individual cancer center's achievement.

Despite improved outcomes with new treatment and targeted therapies, patients with cancer continue to be afflicted by distressing symptoms and serious toxicities, which affect daily functioning and quality of life.

Architects can tailor new buildings to oncology’s specific needs and Arizona Oncology built its newest facility from the ground up rather than renting generic offices.

When it comes to treating older populations for cancer, it’s often the case that the only available data are based on trials of younger patients in far healthier condition.